New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

EXCLUSIVE: Retired David Mather was dealt a shocking blow when told his tiredness was stage-IV lung cancer - now a new UK ...

The BC Cancer Foundation has launched a $6.8 million fundraising campaign to expand provincial immunotherapy research program ...

The following is a summary of “Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer,” published in ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Glenmark Pharmaceuticals reports strong revenue growth and expansion plans for dermatology and respiratory portfolios in ...

Detailed price information for Bio-Path Holdings (BPTH-Q) from The Globe and Mail including charting and trades.